An updated systematic review of 38 randomized controlled trials enrolling 25,816 adults without diabetes confirms that GLP-1 receptor agonists produce significant weight loss, ranks tirzepatide as the most effective currently available agent, and finds experimental coagonist peptides can produce…
An updated systematic review of 38 randomized controlled trials involving 25,816 adults with overweight or obesity but no diabetes has concluded that GLP-1 receptor agonists produce significant weight loss, that tirzepatide is the most effective agent currently available, and that experimental coagonist peptides still in development show even larger effects. The review, led by Areesha Moiz, is an update of the same group's earlier systematic review and adds 14 newly identified randomized controlled trials. It was published in 2026 in Annals of Internal Medicine , the journal of the American College of Physicians, under the DOI 10.7326/annals-25-05519, and it comes from researchers at the Jewish General Hospital and McGill University .
Because it is an update rather than a first analysis, its contribution is cumulative. The 14 additional trials brought the pooled sample to 25,816 adults and introduced newer GLP-1-based coagonists into the evidence base. The resulting ranking placed tirzepatide, a dual GIP and GLP-1 receptor agonist, at the top of the currently available class, while noting that some experimental treatments were associated with weight loss exceeding 20% of body weight. The authors concluded that GLP-1-based therapies offer effective weight-loss options for people without diabetes, and they reached that conclusion across a mix of injectable and oral formulations.
The population matters as much as the result. Adults with overweight or obesity without diabetes are the group driving the rapid expansion of GLP-1-based therapies for weight management, a use distinct from the glycemic control that originally defined the class. The review consolidates that evidence at a moment when the class is diversifying and the efficacy ceiling is still moving. A summary of the review, edited by Sadie Harley, Scientific Editor, and Andrew Zinin, Chief Editor, at the science news outlet Medical Xpress, was published September 1, 2026.
The 14 newly identified trials changed the review's picture in two ways. They added statistical power to the pooled estimate of weight loss, and they brought newer GLP-1-based coagonists, agents that pair GLP-1 receptor activation with additional metabolic hormone signaling, into the analysis. Some of these emerging treatments were associated with weight loss exceeding 20% of body weight, a magnitude that no currently available agent delivers reliably across a broad population. That figure, it should be stressed, was reported only for some emerging treatments, not for the entire class. It has nonetheless become the informal benchmark for what a next-generation obesity therapy should clear, because the broader surgical and pharmacologic literature places 20% total weight loss at the range where obesity-related complications begin to reverse meaningfully.
The efficacy ranking inside the review is tiered. Among currently available GLP-1-based treatments, tirzepatide produced the greatest weight loss. The experimental coagonists showed larger effects still, the clearest signal in the review about the direction of the field: the efficacy ceiling for peptide-based obesity therapy has not been reached. Consistency across 38 trials is what a pooled analysis buys that no single trial can, since the weight-loss signal survived different drugs, doses, titrations, and trial settings. An update design adds another layer of assurance, because it tests whether the earlier finding holds as new evidence accrues rather than resting on a fixed set of studies.
Safety reporting ran along familiar lines. Gastrointestinal adverse effects were the most common adverse effects across all therapies, a pattern that held for every agent in the review. Serious adverse events and deaths were rare in the included trials, and the authors identified no new safety concerns. That combination, a well-defined gastrointestinal signal and a thin tail of serious events, is the standard safety profile for this class, and it is the benchmark against which next-generation coagonists will be measured. The safety finding does have a boundary: trials of this size and duration cannot detect rare events with confidence, so "no new safety concerns" is a statement about the absence of a signal in the trials, not a proof of long-term safety.
The review is a systematic review of randomized controlled trials, the strongest available design for questions of drug efficacy. The included trials enrolled adults with overweight or obesity without diabetes, a population choice that isolates weight effects from the glycemic effects that dominate in diabetes trials. The prespecified endpoints were change in body weight, change in BMI, change in waist circumference, change in blood pressure, and safety outcomes including gastrointestinal adverse events, serious adverse events, and deaths.
The primary result was unambiguous: participants taking GLP-1 receptor agonists lost significantly more weight than those receiving placebo. The anthropometric endpoints, BMI and waist circumference, moved in the same direction. Blood pressure was measured as part of the cardiometabolic assessment, though the public summary of the review does not report the blood pressure results. Because every included study was randomized and placebo-controlled, the pooled weight-loss signal is unlikely to be explained by the lifestyle changes that accompany participation in weight-loss trials. The public summary also does not report the review's risk-of-bias assessment, its heterogeneity statistics, or the method by which missing data were handled, all of which matter in obesity trials, where attrition is typically high.
The design has hard limits. A systematic review pools trials of different drugs, doses, and durations, so the ranking of tirzepatide above other agents is a comparison of trial-level averages, and the public summary does not indicate whether it rests on direct head-to-head trials or on indirect comparison across separate placebo-controlled studies. The review cannot establish how long weight loss persists after treatment stops, because the trials themselves are typically shorter than the treatment horizons patients face, and the biology of the class points to weight regain after discontinuation as the expected pattern, since appetite suppression is contingent on continuing drug exposure. A monitored trial population also cannot predict performance in unsupervised real-world use, where adherence, product quality, and dosing discipline all drift. Trial durations, dosing regimens, and follow-up lengths are not reported in the public summary, which further limits any claim about durability. Because the review covers adults without diabetes, its results may not generalize to people with diabetes, whose glycemic responses, concomitant medications, and safety profiles differ.
GLP-1 is an incretin hormone released by intestinal L cells after meals. Its best-known action is glucose-dependent insulin secretion from pancreatic beta cells, the property that justified its development for type 2 diabetes. But GLP-1 receptors are also expressed in hypothalamic nuclei that regulate appetite, in brain-stem circuits that process visceral signals, and on vagal afferents from the gut. Activation of these receptors reduces food intake, slows gastric emptying, and dampens the rewarding properties of food. In people without diabetes, it is these central and gastrointestinal actions, not insulin secretion, that drive weight loss.
Native GLP-1 is degraded by the enzyme DPP-4 within minutes, which is why the drugs in this class are engineered peptides, resistant to that cleavage and modified for prolonged half-lives so that dosing is weekly rather than continuous. The pharmacology also explains the adverse-event profile. Nausea, vomiting, diarrhea, and constipation are direct consequences of GLP-1 receptor signaling on gut motility and the brain-stem circuits that generate visceral malaise, and these effects are most pronounced during dose escalation. That gastrointestinal effects dominated across all 38 trials, while serious adverse events stayed rare, points to on-target pharmacology rather than off-target toxicity. For peptide developers, tolerability is set by receptor biology: every new coagonist must manage the same gastrointestinal signal while adding efficacy elsewhere, which is why titration schedules matter as much as the peptide sequence itself.
Tirzepatide extends that pharmacology by engaging a second incretin receptor. It is a dual agonist of the GIP and GLP-1 receptors, a design explicit in the registered trial NCT07609160, which studies combined GLP-1/GIP dual agonist therapy. GIP was long viewed mainly as a fat-storage hormone, and the mechanistic basis of the dual-agonist advantage remains a live scientific question, including whether the added efficacy comes from GIP receptor signaling in the brain, from improved beta-cell function, or from GIP's effects on adipose-tissue lipid handling. The experimental coagonists in the updated review push the same logic further by adding one or more additional hormonal axes. The likely logic is that GLP-1 receptor activation mainly reduces intake, while complementary receptor signaling may raise energy expenditure, improve nutrient partitioning, or suppress appetite through independent circuits, which is the plausible basis for the weight losses exceeding 20% that the review attributes to some emerging treatments.
Peptide Atlas's internal registry files show how far tirzepatide has moved beyond its original indications. The database holds 251 registered clinical trials for the molecule, with a phase breakdown on file of 5 phase 2 trials, 2 phase 4 trials, and 1 phase 3 trial, and 10 trials currently listed as recruiting. Phase designations are on file for only a small subset of the registry entries, a common pattern in trial registries, where such fields are often left incomplete. The same file indexes 188 PubMed-indexed papers, and Peptide Atlas maintains an internal reference page for the peptide at https://peptideatlas.co/peptides/tirzepatide.
The recruiting trials on file illustrate the expansion of the research agenda:
These registrations answer, in advance, several of the open questions a weight-focused review cannot address. NCT07609160 measures muscle morphology and physical function under combined GLP-1/GIP therapy with structured exercise, directly confronting the concern that rapid weight loss removes lean tissue along with…
Peptides referenced: Tirzepatide, GLP-1.
Related reading: Employers Drop GLP-1 Weight-Loss Coverage as Costs Climb and Use Rises, Combination therapy, not stronger GLP-1s, will define obesity care, Energean shares slide 12.3% in 2026 while Brent holds above $92, Seoul seizes 4,155 illegal Wegovy and Mounjaro imports in six months.